Back

Explore every episode of the podcast The Biotech Startups Podcast

Dive into the complete episode list for The Biotech Startups Podcast. Each episode is cataloged with detailed descriptions, making it easy to find and explore specific topics. Keep track of all episodes from your favorite podcast and never miss a moment of insightful content.

Rows per page:

1–50 of 295

TitlePub. DateDuration
🧬 The Disease Signal Shows Up Before Symptoms | Ilya Burkov (1/4)16 nov. 202600:34:44
Ilya Burkov is Global Head of Scientific AI & Healthcare at Nebius. Ilya's parents had one rule for every childhood ambition, astronaut, fireman, chef: get a foundation first, then choose. He took it seriously. Sports year round, science projects, Scouts trips, and around ten A levels, because biology, law, electronics, and further maths all seemed worth knowing. Where did the road really start? A hospital, he says, where he volunteered as a teenager, brought tea to long-term patients, and kept noticing that homes had Dysons while wards had old fans.
🧬 The $500 Lab That Started a Company | James Evans Rerelease (3/3)12 nov. 202600:17:50
You need a lab. James Evans found hoods for $500, looked at JLABS in San Diego, and walked away because the price and the fit were wrong. A decade later the company still hasn't taken the predetermined fundraising staircase. He went for a walk before the taping, told his wife those other podcast guests were rock stars, and landed on the only label that fit: scrappy.
🧬 Science Is Twenty Percent of the Problem | James Evans Rerelease (2/3)09 nov. 202600:21:50
Paul Matsudaira took a job in Singapore, and James Evans did not wake up one morning craving entrepreneurship. He left MIT's Whitehead Institute, bounced through venture-backed biotechs, and got a baptism of fire defending data in rooms that wanted a fight. One San Diego client won a contract, and that was enough to plant PhenoVista in California with a year of runway and no paying customers yet.
🧬 Kickflips and Bacterial Pellets Built a Founder | James Evans Rerelease (1/3)05 nov. 202600:27:36
James Evans calls himself a late starter. Childhood in the UK was skateboarding and video games, not science kits. His dad was an engineer and his mom was a nurse, which only looks like a straight line if you draw it afterwards. Science wasn't in the house. Soccer was mainstream. Skateboarding was not, and that counterculture stubbornness is the part he still recognizes in company building.
🧬 Almost $100 Million. No Venture. | Steve Visco Rerelease (3/3)02 nov. 202600:36:31
Steve Visco grew PolyPlus Battery Company on government contracts instead of a stack of tiny SBIRs. Lawrence Berkeley had already taught him how to write large proposals. The danger, he says, is chasing money that pulls the company off its North Star. Once you sign, you cannot renegotiate the work. You get reports, audits, and no BMWs in the parking lot. ARPA-E will kill a grant that stalls. His grant-writing rule is the same as a venture pitch: why should anyone care, who is on the team, and don't ask for too little.
🧬 “We're Going to Burn Your Company to the Ground” | Steve Visco Rerelease (2/3)29 oct. 202600:34:05
Steve Visco's spinout found its first CEO in the audience. Rudolph Hurwich had already built Dymo, cashed out, and was hunting for another shot at something big. He offered to raise the angel round and take the job when Steve said he wasn't ready. The founding four were faculty: Steve, Lutgard De Jonghe at Berkeley, Michel Armand in Montreal and Grenoble, and Meilin Liu at Georgia Tech.
🧬 He Chose Santa Barbara Over Icebergs | Steve Visco Rerelease (1/3)26 oct. 202600:35:22
Steve Visco was an introverted kid with a microscope, pond water, and books on Louis Pasteur and Jonas Salk. School science lagged years behind what he was already doing at home. Literature almost pulled him into writing instead of the lab. He still treats writing as a leadership skill, because too many scientists cannot explain why their work matters. A high-school rock band got him used to being watched. That comfort later showed up in grant pitches.
If It's Getting More Complex, You're Going the Wrong Way | Scott Chetham (4/4)22 oct. 202600:40:45
Scott Chetham explains why he left Google and Verily to tackle the unglamorous planning work that slows clinical development. He recounts sketching the company in Costa Rica, raising a pre-napkin-stage round with Polaris, finding an early customer, and adapting when COVID-19 disrupted pharma economics.
The Clinical Trial Bottleneck Is Not Discovery | Scott Chetham (3/4)19 oct. 202600:30:38
The conversation then moves to the decisions that determine whether a trial succeeds: what to measure, whom to enroll, and when to measure it. Scott uses Amgen's osteoporosis strategy to show how a focused endpoint and staged market entry can outperform an attempt to capture everything at once.
Knowledge Is Now a Commodity | Scott Chetham (2/4)15 oct. 202600:34:15
The conversation then turns to scaling teams through uncertainty. Scott shares how company growth creates organizational whiplash, why founders often underestimate the need for change management, and how leaders can stay close to what employees and customers are actually experiencing.
The Hard Part Starts After the Demo | Scott Chetham (1/4)12 oct. 202600:35:17
Scott Chetham traces the influences that shaped his path into life sciences, from growing up on Australia's Gold Coast and watching his parents build careers through work and education to studying the intersection of engineering and medicine. He shares how a combined degree, early exposure to hospitals, and an unusual appetite for difficult problems pushed him toward biomedical research.
Letting Go Is a Leadership Skill | Leslie Loveless (4/4)08 oct. 202600:37:01
As Slone Partners grew beyond its original five-person team, Leslie Loveless had to confront one of the hardest parts of leadership: letting go. She talks about delegation, resisting the urge to rewrite everyone else's work, and learning that a different approach can still be the right approach.
The Employee Number Five Leap That Built a Relationship Business | Leslie Loveless (3/4)05 oct. 202600:33:13
Leslie Loveless joined Slone Partners after a major personal transition, leaving a large healthcare company to become employee number five at a small recruiting firm. She hadn't worked in recruiting before, and at the time, she didn't fully appreciate how big the leap would be.
Winning President's Club with Zero Sales Experience | Leslie Loveless (2/4)01 oct. 202600:27:24
Leslie Loveless leaves the classroom for pharmaceutical sales in 1999, a coveted industry at the time. She describes the culture shock of moving from a school building into a territory-based role, where her days meant driving between providers, managing her own schedule, and learning to sell one to one.
How Teaching High School Prepares You to Run a Company | Leslie Loveless (1/4)28 sept. 202600:34:30
Leslie Loveless starts at the beginning: growing up in a close-knit Indiana family, watching her father build a career as a pharmacist, and learning early that education mattered even if the eventual career path was left up to her.
The Catalyst Mindset Behind a Lean Biotech | Örn Almarsson (4/4)24 sept. 202600:25:08
He then turns to company building at Axelyf: in vivo cell reprogramming for solid tumors, modular lipid nanoparticles, AI-informed discovery, external partners, and a deliberately lean operating model. The conversation closes with the mentors, expectations, and leadership philosophy shaping his next chapter.
The Delivery Problem Behind Moderna's Breakthrough | Örn Almarsson (3/4)21 sept. 202600:29:11
The conversation covers layoffs, company transformation, patent cliffs, biotech's feast-and-famine cycles, modified mRNA, and the effort required to scale production from tiny academic batches to grams and kilograms.
Leaving Merck to Build a Biotech From Scratch | Örn Almarsson (2/4)17 sept. 202600:30:08
At Merck, a three-month visa detour exposed Örn to another laboratory and reinforced the value of adaptability. He then describes leaving a secure role for Transform Pharmaceuticals, building a small team and collaborative culture, developing new formulation technologies, and helping create the patents and assets that led to a Johnson & Johnson acquisition.
How a Guitarist Became a Drug Delivery Pioneer | Örn Almarsson (1/4)14 sept. 202600:25:39
He describes his first research opportunity at the University of Iceland, an early industry project in Copenhagen, and the mentors who pushed him toward bioorganic chemistry. The conversation follows his move to UC Santa Barbara, his work with Tom Bruice and Alex Klibanov, and the networking connection that led to Merck.
Don't Build Your Own Cathedral: The Hidden Cost of Lab Space | Philip Borden (4/4)10 sept. 202600:43:22
Philip breaks down the hidden costs of traditional lab leases, from equipment maintenance and utilities to medical waste, freezer alarms, and unused square footage. He explains how flexible space can help emerging companies stay focused on milestones while preserving critical capital.
The Biotech Deal That Became a Leadership Crisis | Philip Borden (3/4)07 sept. 202600:30:02
Philip Borden describes leaving Frazier Healthcare Partners for Harvard Business School, where the case method broadened his perspective beyond healthcare and investing. He explains why he returned to healthcare investing after graduation.
Cold Calling Your Way Into Venture Capital | Philip Borden (2/4)03 sept. 202600:21:08
Philip Borden explains how realizing he did not want to pursue a PhD or spend his career at the lab bench led him toward venture capital. With a molecular biology degree, limited finance experience, and a list of biotech VC firms, he picked up the phone and cold-called his way into Frazier Healthcare in Seattle.
What Rural Indiana Can Teach Biotech Founders About Trust | Philip Borden (1/4)31 août 202600:17:51
Philip Borden grew up in Plymouth, Indiana, in a family shaped by agriculture. He talks about his grandparents' farms, his father's work as an agricultural lender, and the early lessons he absorbed about local businesses and long-term relationships.
🧬 Making Lab Data Actionable Through Automation | Nathan Clark Rerelease (4/4)27 août 202600:34:13
In this part of the podcast, Nathan Clark explains how Ganymede approaches data integration and automation in life sciences. He discusses why lab instruments and workflows require customized connectors, how a developer platform can help teams adapt integrations quickly, and why moving data online is only part of the challenge.
🧬 Why Wet-Lab Data Needs More Than ETL | Nathan Clark Rerelease (3/4)24 août 202600:29:37
Nathan Clark walks through his work at Benchling, where he managed the Insights business intelligence product and helped develop an early machine learning effort. He explains why operational wet-lab data is fundamentally different from omics data, and why the relationships between samples, programs, instruments, locations, and people matter as much as the experimental results.
🧬 Product Thinking, Scientific Progress, & the Work of Building | Nathan Clark Rerelease (2/4)20 août 202600:27:46
The conversation then turns to product management. Nathan describes the discipline as understanding why a product should exist, grounding decisions in user needs, and translating research into what a team builds. His advice for early-stage founders is direct: stop coding until they've done enough customer research to understand the problem.
🧬 Execution, Liquidity, & Founder Lessons | Nathan Clark Rerelease (1/4)17 août 202600:36:48
Nathan Clark reflects on the formative influence of his entrepreneurial father, who showed him that business and even home building are learned through research, effort, and execution rather than secret insight. Nathan also discusses his unconventional high school experience, his decision to study business and finance at the University of North Carolina, and the early interest in biology and futurism that stayed with him.
🧬 AI, Mechanisms, & the Next Wave of Drug Discovery | David Li Rerelease (4/4)13 août 202600:27:08
David Li explains how a research question about mischaracterized drug targets became the starting point for Meliora Therapeutics. He describes how CRISPR experiments and follow-up biology challenged the accepted mechanism for cancer drugs, and how the company uses AI and machine learning to connect chemistry, biology, biomarkers, and patient populations.
🧬 De-Risking Biotech's Biggest Bets | David Li Rerelease (3/4)10 août 202600:20:20
In this part of the podcast, David Li, CEO and co-founder of Meliora Therapeutics, reflects on his experience helping build Everest Detection around the challenge of finding lung cancer earlier. He discusses the potential of a noninvasive, blood-based test, why lung cancer can be difficult to detect in blood, and how access to early-stage clinical samples helped the team investigate the problem.
🧬 Choosing Conviction Over Convention in Biotech | David Li Rerelease (2/4)06 août 202600:25:07
In this part of the podcast, David Li reflects on leaving finance after realizing that an investing career would not give him the tangible impact he wanted. He explains what KKR taught him about business and patient needs, then describes the team-and-market test that led him to Benchling.
🧬 The Outsider Mindset Behind Successful Biotech Founders | David Li Rerelease (1/4)03 août 202600:30:08
In this part of the podcast, David shares how the Roy Vagelos Life Sciences and Management dual degree program at the University of Pennsylvania opened his eyes to the possibilities of combining scientific discovery with business acumen. A pivotal summer internship with Arie Belldegrun at UCLA—during which Kite Pharma was born—planted the seed for his future in life sciences entrepreneurship. He also discusses his transition into finance, landing at Goldman Sachs, and the lessons learned from sitting in boardrooms alongside C-level executives at critical moments in companies' life cycles.
🧬 This Ex-Googler Replaced a Whole Drug R&D Team | Javier Tordable (4/4)30 juil. 202600:59:03
In this part of the podcast, Javier Tordable unpacks why he left Google to solo found Pauling AI and how its agentic platform automates computational chemistry—from docking to ADMET—collapsing months into days.
🧬 From Games to Cancer Research: Why Drug Discovery Is an Economics Problem | Javier Tordable (3/4)27 juil. 202600:22:44
In this part of the podcast, Jon and Javier explore Javier's years as technical director in Google's Office of the CTO, where he worked with the world's biggest gaming companies—Nintendo, Ubisoft, Electronic Arts, and Unity—helping them leverage Google Cloud technology. Javier then shares the deeply personal story of how his father's passing from cancer became the turning point that pulled him into life sciences, and how he taught himself biochemistry and pharmacology through Harvard Medical School's HMX program.
🧬 16 Years at Google Taught Me How to Scale From 1 to 150 People | Javier Tordable (2/4)23 juil. 202600:28:34
In this part of the podcast, Javier Tordable shares his early career journey—from starting at Microsoft to spending 16 years at Google as a Staff Engineer and Technical Director. He reflects on the engineering-driven culture at Microsoft and the welcoming environment that shaped his foundation in tech.
🧬 Video Games & a Whim Led Me to Microsoft | Javier Tordable (1/4)20 juil. 202600:26:28
In this episode of The Biotech Startups Podcast, Jon Chee sits down with Javier Tordable, founder and CEO of Pauling AI, a company building the first fully autonomous drug discovery platform that enables scientists to go from a research idea to validated drug molecules in days, not years. Named after Linus Pauling, the only person in history to win two unshared Nobel Prizes, the company reflects Javier's conviction that first principles engineering can be applied to one of science's most consequential problems.
🧬 Crossover Investing, Gene Therapy & LP Trust | Stephanie Sirota Rerelease (3/3)16 juil. 202600:30:24
In this episode of The Biotech Startups Podcast, host Jon Chee continues his conversation with Stephanie Sirota, Partner and Head of Strategic Partnerships at RTW Investments, as she traces RTW’s evolution from a lean public-equity fund into a major life sciences platform spanning crossover investing, company creation, and global commercialization. Stephanie explains how RTW built the modern crossover ecosystem, why they chose to found Rocket Pharma instead of a fleet of gene therapy startups, and how a disciplined, science-first research process underpins the firm’s long-term, concentrated investing strategy and deep alignment with LPs and portfolio founders.
🧬 Cycles, Conviction & Royalty Capital in Biotech Investing | Stephanie Sirota Rerelease (2/3)13 juil. 202600:32:44
In this episode of The Biotech Startups Podcast, host Jon Chee continues his conversation with Stephanie Sirota, Partner and Head of Strategic Partnerships at RTW Investments, as she reflects on her path from Lehman Brothers investment banking to macro hedge funds and ultimately biotech-focused investing and firm building. Steph shares how journalism training shaped her strategic thinking, what she learned from navigating multiple market crises, and how those lessons inform RTW’s approach to cycles, institutional architecture, and innovative funding models like royalty vehicles in today’s prolonged biotech bear market.
🧬 Competition, Coaching & Curiosity: The Investor’s Mindset | Stephanie Sirota Rerelease (1/3)09 juil. 202600:24:08
In this episode of The Biotech Startups Podcast, Jon Chee sits down with Stephanie Sirota, partner and head of strategic partnerships at RTW Investments, to explore how a coddled yet cosmopolitan upbringing, years of elite tennis competition, and a humanities-rich education at Columbia shaped her mental toughness, leadership style, and approach to partnering with life sciences innovators. From sports psychology and coaching to the value of breadth before specialization, Stephanie reflects on the experiences that built her resilience and curiosity long before she helped transform RTW into a leading life sciences investment firm.
🧬 Transforming Food Systems with Lactoferrin & Precision Fermentation | Fengru Lin Rerelease (3/3)06 juil. 202600:28:29
In this episode of The Biotech Startups Podcast, Jon Chee sits down with Fengru Lin, CEO & co-founder of TurtleTree, who is leveraging precision fermentation and a people-first culture to bring the high-value milk protein lactoferrin to market while reshaping how the food system serves both consumers and farmers. They discuss TurtleTree's strategic refocus from cell-based milk to commercially viable ingredients, the importance of business-centric leadership in biotech, and how thoughtful team-building enables faster execution, better fundraising narratives, and earlier commercialization.
🧬 Sales Funnels, Patents, & Cell-Based Milk: TurtleTree’s Early Bets | Fengru Lin Rerelease (2/3)02 juil. 202600:24:34
In this episode of The Biotech Startups Podcast, host Jon Chee continues his conversation with Fengru Lin, CEO and co-founder of TurtleTree. Fengru shares how rigorous sales training at Salesforce and entrepreneurial autonomy at Google Cloud shaped her approach to customers, investors, and organizational change—then traces how a cheese-making hobby, poor dairy supply chains, and exposure to cell-based meat and seafood startups led to TurtleTree’s founding, early patents, and strategic pivot toward precision fermentation of high-value milk proteins.
🧬 From Hong Kong Childhood to Global Sales: Connecting the Dots | Fengru Lin Rerelease (1/3)29 juin 202600:22:52
In this episode of The Biotech Startups Podcast, Jon Chee sits down with Fengru Lin, CEO and co-founder of TurtleTree, a biotech company using precision fermentation to produce LF+, the world’s first sustainably made lactoferrin, and ultimately reimagine how food is produced. Drawing on a nontraditional path into biotech—from Girl Guides in Singapore to sales roles in transactional security and global regulatory environments—Fengru shares how an early love of planning, operations, and people has shaped her approach to leadership and company building.
🧬 AI in Biotech: When Sustainable Growth Replaces Hype | Mati Gill (4/4)25 juin 202600:21:01
In this final episode of The Biotech Startups Podcast series, Jon Chee sits down with Mati Gill, CEO of AION Labs, to unpack where AI value is actually being created in biopharma—and what comes next. Mati lays out three pillars driving a post-hype phase of sustainable growth, explains why the industry is structurally conservative for good reasons, and shares how AION Labs is already preparing for the quantum computing wave before it arrives.
🧬 Venture Studio Model: Building the Future of AI Drug Discovery | Mati Gill (3/4)22 juin 202600:47:24
Jon Chee sits down with Mati Gill, CEO of AION Labs — an Israeli venture studio backed by AstraZeneca, Merck, Pfizer, Teva, AWS, and the Israel Biotech Fund. Mati breaks down how AION Labs builds AI-native pharma companies from the ground up: industry-grade problem statements, multidisciplinary teams, and pharma partner POC commitments locked in before a startup is formed.
🧬 From Law School to Teva: Learning a 45,000-Person Organization | Mati Gill (2/4)18 juin 202600:36:04
In this episode of The Biotech Startups Podcast, Jon Chee sits down with Mati Gill, CEO of AION Labs. Mati traces his path from juggling a minister's bureau with Israeli law school to joining Teva as an intern with no private-sector experience, then learning a 45,000-person org from the chart up — until Teva's financial crisis handed him the mandate to build the innovation program that became AION Labs.
🧬 The Rule of Three: Career, Family & One Other Thing | Mati Gill (1/4)15 juin 202600:24:49
In this episode of The Biotech Startups Podcast, Jon Chee sits down with Mati Gill, CEO of AION Labs—a first-of-its-kind AI venture studio backed by Teva, Pfizer, AstraZeneca, Merck, and Amazon Web Services. Before AION Labs, Mati spent six years in the IDF, ran a minister's bureau, and rose from legal intern to global legal COO at Teva over more than a decade. Part one covers the formative years: moving from Columbus, Ohio to Jerusalem at 12, extending military service by three years, and the two teachers who handed him D's and changed how he works.
🧬 From Reactive Data to Predictive Intelligence: Inside Convoke's Platform | Alex Telford (4/4)11 juin 202600:24:52
In part four, Alex Telford, founder of Convoke, covers the platform architecture and roadmap. He walks through Convoke's modular system—building validated structured datasets from trial registries, regulatory filings, and patents, then stitching them with workflow tools for competitive intelligence and document generation. He breaks down how pharma and biotech customers engage differently, why an "everything app" is a trap, and how Convoke is moving from reactive data storage toward proactive, predictive intelligence.
🧬 Pharma's Coordination Tax & the 2 Paths That Could Actually Disrupt It | Alex Telford (3/4)08 juin 202600:28:00
In this episode, Jon Chee sits down with Alex Telford, founder of Convoke, to examine why large pharma resists AI transformation. Drawing on seven years at Charles River Associates, Alex maps the coordination tax of siloed orgs, the tacit knowledge lost when experts retire, and why software efficiency is the wrong axis to compete on. His frame: factory electrification — the gains don't arrive until you redesign the whole org around the technology.
🧬 AI Psychosis, Coordination Tax & the Limits of LLMs | Alex Telford (2/4)04 juin 202600:46:21
In this episode of The Biotech Startups Podcast, Jon Chee sits down with Alex Telford, founder of Convoke, who spent nearly seven years in biopharma strategy consulting before what he calls "AI psychosis" set him on a different path. Alex traces the arc from biochemistry at Bristol and synthetic biology at UCL to discovering consulting existed only after graduating, joining a boutique Swiss firm two weeks before it was acquired, and learning one core lesson: clients want a recommendation to push back on, not a data dump.
🧬 From Expat Kid to Founder: Science, Curiosity & the Long Road to Conviction | Alex Telford (1/4)01 juin 202600:22:06
In this episode of The Biotech Startups Podcast, Jon Chee sits down with Alex Telford, founder of Convoke, who raised $8.6 million to build the AI-native operating system for biopharma. Part one traces his path from an expat childhood across Switzerland, Germany, and Spain — shaped by international schools, disappearing friendships, and a New Scientist subscription — through biochemistry at Bristol and into a synthetic biology master's at UCL that promised biological engineering and delivered toggle switches.
🧬 The Groomed Trail: Building a Women's Health Pipeline the Bold Way | Sabrina Johnson (4/4)28 mai 202600:42:38
In this episode, Jon Chee sits down with Sabrina Johnson, President and CEO of DARÉ Bioscience, to unpack the founding arc of a company built on a singular conviction: women's health is not a niche. Sabrina explains the choice to go public via reverse merger in 2017 to access capital in a space where only 1% of private healthcare investment funds women-specific conditions, and breaks down the groomed trail philosophy behind XACIATO, DARE to PLAY Sildenafil Cream, a pivotal Phase 3 contraceptive, and an ARPA-H-funded HPV treatment—all with 25 people and $75M+ in non-dilutive funding.
© My Podcast Data · Independent project · Data from Apple & Spotify